A Fungal Defensin Targets the SARS−CoV−2 Spike Receptor−Binding Domain
Coronavirus Disease 2019 (COVID−19) elicited by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS−CoV−2) is calling for novel targeted drugs. Since the viral entry into host cells depends on specific interactions between the receptor−binding domain (RBD) of the viral Spike protein and the me...
Main Authors: | Bin Gao, Shunyi Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Journal of Fungi |
Subjects: | |
Online Access: | https://www.mdpi.com/2309-608X/7/7/553 |
Similar Items
-
Coronavirus (SARS-CoV-2): Preventions, keys to diagnosis and treatment of SARS-CoV-2
by: Kuldeep Singh Patel, et al.
Published: (2020-03-01) -
Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike
by: João Trigueiro-Louro, et al.
Published: (2020-01-01) -
Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus
by: Irina Leneva, et al.
Published: (2021-08-01) -
Antibody Engineering Towards Enhancement of Spike Protein SARS-COV-2 -m396 Binding Affinity
by: Fateme Sefid, et al.
Published: (2021-01-01) -
Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
by: Igor de Andrade Santos, et al.
Published: (2020-08-01)